ESTRO 38 Abstract book

S1175 ESTRO 38

toxicities observed, but no grade 3 toxicity or higher was described. Conclusion Several prospective trials demonstrated that the majority of local recurrences (69-90 %) arises at the vicinity (1-2 cm) of the tumor bed. Given that it seems rational the use of more conformational techniques with APBI. These techniques allow to spare organs at risk (heart, lung, chest wall and contralateral breast) without compromising the excellent survival outcomes in breast cancer, which is supported by recent results of randomized clinical trials. The interstitial HDR BT is the technique with the longest clinical experience and with strong evidences of non- inferiority in comparison with the standard WBI. These results are in line with our one-institutional analysis with the use of a propensity-score matching methodology. Careful selection of the pts who are most likely to benefit from such approach is crucial for the success of the treatment. EP-2124 Brachytherapy in the treatment of locally advanced cervical cancer: a single center study J. Khalil 1 1 National Institute of Oncology Sidi Mohamed Ben Ab, Radiotherapy, Rabat, Morocco Purpose or Objective Concurrent chemoradiotherapy in combination with brachytherapy is the standard treatment of locally advanced cervical carcinoma. Brachytherapy has, in fact, became an integral component of cervical cancer treatment as it confers many dosimetric benefits insuring better local control and survival rates when compared to external beam radiation alone. Lately, a decline in brachytherapy use has been noticed either because of the lake of expertise or because of the radiation oncologist’s trend to replace brachytherapy with the newest radiotherapy techniques. The aim of our study is to evaluate the role of brachytherapy as a boost technique in locally advanced cervical carcinoma. Material and Methods Our study is a retrospective one including 387patients treated for locally advanced cervical carcinoma, between January 2007 and December 2007, in the national institute of oncology Morocco. 179 patients received external beam pelvic irradiation combined with brachytherapy, while 208 patients were treated with external beam radiotherapy alone (EBRTA). Results The mean age for the whole group was 47.7 (range 26–78 years), and the median age was 46 years, there was no significant difference between the two groups. The past medical history was also identical between the two groups. All patients received their treatment in our institution during the same time period, and by the same specialized gynecologic oncologists and radiotherapists. Differences between the two groups concerned tumor stage, tumor size, treatment doses and time duration. Local control rate at 5 years was of 80.7% in the brachytherapy group and 56.8% in the EBRTA arm (Pearson chi-square; p <0.0001). As to survival rates, there was a statistically highly significant difference in all of 5-year overall survival (73% and 57.3% for brachytherapy and EBRTA arms respectively, p<0.001), cancer-specific survival (63.5 % for the brachytherapy group and 47.6% in the EBRTA group, p=0.002), and disease-free survival (log- rank test; p <0.00001). Patients in the brachytherapy arm showed less treatment related toxicities. Conclusion Our results are concordant with those previously reported in the literature and stating that brachyterapy should still Electronic Poster: Brachytherapy: Gynaecology

Results The median follow-up was 81 (3-167 months). There were no significant differences between the APBI and WBI groups in terms of age, stage, immunohistochemical analysis (hormone receptors, HER2, Ki-67), surgical margins, lymphovascular invasion and use of adjuvant hormone therapy. The 5-year recurrence-free survival and overall survival were 91.7 % and 100 %, respectively. No significant difference of recurrence-free ( p=0.564 ) and overall ( p=0.113 ) survival was found. The treatment with APBI was well tolerated with no late toxicity reported in 60 % of pts. Breast edema and fibrosis were the main